Tuberculosis is one of the deadliest infectious diseases worldwide and the prevalence of
latent tuberculosis acts as a huge roadblock in the global effort to eradicate tuberculosis …

Novel treatment strategies for tuberculosis are urgently needed. Many different preclinical
models assessing anti-tuberculosis drug activity are available, but it is yet unclear which …

Tuberculosis (TB) drug development has made substantial progress in the past decade.
There are currently at least ten drugs being evaluated in clinical trials. Some belong to …

Human tuberculosis (TB) is primarily caused by Mycobacterium tuberculosis (Mtb) that
inhabits inside and amidst immune cells of the host with adapted physiology to regulate …

Background Several nonclinical drug-development tools (DDTs) have been used for
antituberculosis drug development over several decades. The role of the DDTs used for …

Tuberculosis (TB) is a major cause of morbidity and mortality worldwide. The emergence
and rapid spread of drug-resistant M. tuberculosis strains urge us to develop novel …

Management of tuberculosis, already a global health emergency, is becoming increasingly
challenging with extensive misuse of second line drugs and their inaccessibility to eighty …

More than two decades have elapsed since the publication of the first genome sequence of
Mycobacterium tuberculosis (Mtb) which, shortly thereafter, enabled methods to determine …

Highlights•Prodrugs are over-represented among hits from phenotypic
screens.•Hypomorphs are versatile tools for use in TB drug target validation.•Innovative …

Due to the rise of drug-resistant forms of tuberculosis, there is an urgent need for novel
antibiotics to effectively combat these cases and shorten treatment regimens. Recently, drug …